Combination of oral anticoagulant and platelet inhibitor drugs: Focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement

European Heart Journal, Supplement

Volumn 3, Issue Q, 2001, Pages

  Schror, K ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aspiri; Clopidogrel; Oral anticoagulants; Phenprocoumon; Valve replacement; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COUMARIN ANTICOAGULANT; DERMATAN SULFATE; PENTASACCHARIDE; PHENPROCOUMON; THROMBIN INHIBITOR; TICLOPIDINE; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ARTICLE; BLEEDING; DOSE CALCULATION; DRUG EFFECT; GERMANY; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035661863     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90044-6     Document Type: Article

References (25)

1. Practical aspects of anticoagulant therapy
2. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
3. Recommendations for prevention of thromboembolism in heart valve diseases
4. Intensity of oral anticoagulant therapy after heart valve replacement
5. Molecular mechanisms and indicators of thrombogenesis after heart valve replacement
6. High risk of thromboemboli early after bioprosthetic cardiac valve replacement
7. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
8. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
9. Ticlopidine and clopidogrel
10. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses
11. Oral anticoagulation alone or in combination with aspirin: Risks and benefits
12. Inhibition of thrombocyte aggregation after heart valve replacement
13. Trial of different intensities of anticoagulation in patients with prosthetic heart valves
14. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement
15. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves
16. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
17. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves
18. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis
19. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement
20. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: A clinical and transesophageal echocardiographic study
21. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical prosthetic heart valves
22. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting
23. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model
24. Perspectives on factor Xa inhibition
25. A rationale for targeting antithrombotic therapy at the vessel wall: Improved antithrombotic effect and decreased risk of bleeding